Abstract
Probiotic viability from manufacture to colonic delivery is compromised by thermal processing, oxidative storage conditions, and sequential gastrointestinal (GIT) stresses, with cumulative losses exceeding 8 log10 CFU in unprotected preparations. Encapsulation addresses this challenge by shielding cells within protective matrices. This review synthesizes current evidence across the full encapsulation value chain. We examine GIT stress physiology from ingestion to colonic fermentation, then analyze encapsulation architectures spanning macro-beads to single-cell metal-phenolic network (MPN) nano-coatings. Wall material performance covering sodium alginate, chitosan, whey proteins, pectin, zein, soy protein isolate, and MPNs is evaluated against six selection criteria. Four industrial processes (ionotropic gelation, spray drying, spray chilling, and freeze drying) are appraised for engineering efficiency. A critical assessment of in vitro digestion models reveals that static INFOGEST 2.0 protocols overestimate in vivo protection by 1-3 log10 CFU relative to human fecal recovery studies, owing to the absence of peristaltic mechanics, mucus interactions, and microbiome competition. Emerging frontiers including synbiotic co-encapsulation, AI-driven formulation optimization, and engineered live biotherapeutic products are discussed. A four-stage validation pipeline static in vitro screening, dynamic model validation, ex vivo/animal confirmation, and stratified human trial is proposed as a translational framework to close the gap between laboratory performance and clinical outcome. No single wall material, process, or validation stage performs optimally across all contexts; the evidence instead supports strain, matrix, and application-specific formulation, verified through staged evidence generation, as the most defensible route from laboratory protection to clinically meaningful gastrointestinal delivery.